Evidence to Practice retweeted
Congratulations to our member @WannJiaLoh for hosting a Lp(a) #Awareness Day in conjunction with Changi General Hospital (CGH).
Her goal was to 'unpack the who, what, why and how's of #lipoprotein(a).'
Find out more information about Dr Wann’s initiative apcmc.net/education/
Evidence to Practice retweeted
This Thursday, 16th March at 8.00pm AEDT via @apsc_office @ProfSNicholls will summarise the results from the CLEAR Outcomes trial. Join Steve and our panel as we discuss this important trial and the new option it presents for patients with statin intolerance.
Join us at our annual Symposium to discuss the latest topical and developing areas in cardiology! Tickets are going fast so register today.
80
If you're after a breakdown of the major Clinical Trials presented at ESC 2022 - we've got you covered!
Register for tickets and join our expert faculty as we discuss the major implications of these results for practice in Australia.
e2pclinicaltrialforum.eventb…
PACIFIC-AMI demonstrating that Asundexian 50mg daily on top of DAPT resulted in near complete (>90%) inhibition of factor Xla inhibition following acute MI #ESCCongress
On top of DAPT there was no increase in significant (BARC 2,3 or 5) or any bleeding with any dose of Asundexian compared with placebo
1
1
The INVICTUS study showing that in RHD-AF, compared to rivaroxaban,VKAs have a lower mortality and reduced ischemic stroke without increasing the risk of major bleeding. VKAs should remain the standard of care in RHD-AF
Evidence to Practice retweeted
DELIVER: In an RCT involving patients with HF and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the risk of the composite outcome of worsening heart failure or CV death. #ESCCongress nej.md/3PJ6Oir
ALL-HEART - Allopurinol added to usual care did not improve outcomes in patients aged over 60 years with IHD (but no gout) #ESCCongress
2
The REVIVED study (Percutaneous Revascularisation for Ischaemic Ventricular Dysfunction) demonstrating that patients with ischaemic cardiomyopathy continue to have high rates of mortality and hospitalisation for HF even with contemporary medical and device therapy.
PCI did not reduce the composite incidence of all-cause mortality or hospitalisation for heart failure at a median of 3.4 years.
1
The DANFLU-1 trial (High-dose vs. standard-dose quadrivalent influenza vaccine in elderly adults) demonstrates that the incidence of hospitalisation for influenza or pneumonia was significantly lower in the QIV-HD group compared to the QIV-SD group.
2
1
The role of high dose flu vaccine in CVD is unresolved however likely the best choice for those 65 years +
ADVOR (Acetazolamide in Acute Decompensated Heart Failure with Volume OveRload) demonstrating that the addition of 500mg IV acetazolamide to standardised IV loop diuretic was associated with a 46% higher incidence of successful decongestion after 3 days. #ESCCongress
DANCAVAS - Screening and intervention to prevent cardiovascular disease. After 5 years, an invitation for comprehensive imaging based CV screening did not significantly reduce all cause mortality among men aged 65-74 years #ESCCongress
2
1















